N-methyl-4-(((2-(methylamino)-6-(pyridin-2-yl)pyrimidin-4-yl)amino)methyl)benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-methyl-4-(((2-(methylamino)-6-(pyridin-2-yl)pyrimidin-4-yl)amino)methyl)benzamide
• 英文别名: N-methyl-4-[[[2-(methylamino)-6-pyridin-2-ylpyrimidin-4-yl]amino]methyl]benzamide
• 化学式: C₁₉H₂₀N₆O
• 分子量: 348.407
• InChiKey: PQLZKIZGFLHPNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  91.8
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  皮考林乙酸乙酯 在 potassium carbonate 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 2.0h， 生成 N-methyl-4-(((2-(methylamino)-6-(pyridin-2-yl)pyrimidin-4-yl)amino)methyl)benzamide
  参考文献：
  名称：

  Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists

  摘要：

  The identification of highly potent and orally bioavailable GPR39 agonists is reported. Compound 1, found in a phenotypic screening campaign, was transformed into compound 2 with good activity on both the rat and human GPR39 receptor. This compound was further optimized to improve ligand efficiency and pharmacokinetic properties to yield GPR39 agonists for the potential oral treatment of type 2 diabetes. Thus, compound 3 is the first potent GPR39 agonist (EC(50)s <= 1 nM for human and rat receptor) that is orally bioavailable in mice and robustly induced acute GLP-1 levels.

  DOI：

  10.1021/ml500240d

文献信息

• Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists
  作者：Stefan Peukert、Richard Hughes、Jill Nunez、Guo He、Zhao Yan、Rishi Jain、Luis Llamas、Sarah Luchansky、Adam Carlson、Guiqing Liang、Vidya Kunjathoor、Mike Pietropaolo、Jeffrey Shapiro、Anja Castellana、Xiaoping Wu、Avirup Bose

  DOI：10.1021/ml500240d

  日期：2014.10.9

  The identification of highly potent and orally bioavailable GPR39 agonists is reported. Compound 1, found in a phenotypic screening campaign, was transformed into compound 2 with good activity on both the rat and human GPR39 receptor. This compound was further optimized to improve ligand efficiency and pharmacokinetic properties to yield GPR39 agonists for the potential oral treatment of type 2 diabetes. Thus, compound 3 is the first potent GPR39 agonist (EC(50)s <= 1 nM for human and rat receptor) that is orally bioavailable in mice and robustly induced acute GLP-1 levels.